Pasadena Private Wealth’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Pasadena Private Wealth’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25,000	Closed	-$33K	–	169
2024 Q3	$33K	Hold	25,000	–	–	0.01%	148
2024 Q2	$190K	Buy	+25,000	New	+$215K	0.04%	138
2024 Q1	–	Sell	-25,000	Closed	-$268K	–	165
2023 Q4	$268K	Buy	25,000 +11,062	+79%	+$79.7K	0.07%	117
2023 Q3	$83.6K	Buy	+13,938	New	+$98.2K	0.03%	92

Other funds holding ONCT

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Pasadena Private Wealth's ONCT Position: Q4 2024 in Review

Pasadena Private Wealth sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 25,000 shares — an estimated $33K sold.

Pasadena Private Wealth first reported a position in ONCT in Q3 2023 and held it in 4 quarters. The position peaked at $268K in Q4 2023. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

Pasadena Private Wealth reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Pasadena Private Wealth sold 25,000 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $33K.
Pasadena Private Wealth first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2023 and held it in 4 quarters.
Pasadena Private Wealth's Oncternal Therapeutics, Inc. Common Stock position peaked at $268K in Q4 2023.
4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Pasadena Private Wealth's 13F filing for Q4 2024, filed 3 Feb 2025.